Abstract
623P VIC regimen (vemurafenib/irinotecan/cetuximab) versus bevacizumab plus chemotherapy as first-line treatment for BRAF V600E-mutated advanced colorectal cancer
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have